These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 11205155)

  • 1. Impaired iron homeostasis in Parkinson's disease.
    Double KL; Gerlach M; Youdim MB; Riederer P
    J Neural Transm Suppl; 2000; (60):37-58. PubMed ID: 11205155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
    Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MB; Riederer P
    Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of neuromelanin on oxidative pathways within the human substantia nigra.
    Double KL; Ben-Shachar D; Youdim MB; Zecca L; Riederer P; Gerlach M
    Neurotoxicol Teratol; 2002; 24(5):621-8. PubMed ID: 12200193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential sources of increased iron in the substantia nigra of parkinsonian patients.
    Gerlach M; Double KL; Youdim MB; Riederer P
    J Neural Transm Suppl; 2006; (70):133-42. PubMed ID: 17017520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relevance of iron in the pathogenesis of Parkinson's disease.
    Sian-Hülsmann J; Mandel S; Youdim MB; Riederer P
    J Neurochem; 2011 Sep; 118(6):939-57. PubMed ID: 21138437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron dysregulation and Parkinson's disease.
    Andersen JK
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S47-52. PubMed ID: 15665414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain iron homeostasis.
    Moos T
    Dan Med Bull; 2002 Nov; 49(4):279-301. PubMed ID: 12553165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron transport in Parkinson's disease.
    Hirsch EC
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E; Puchinger L; Jellinger K; Linert W; Stachelberger H; Jameson RF
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson's disease.
    Friedrich I; Reimann K; Jankuhn S; Kirilina E; Stieler J; Sonntag M; Meijer J; Weiskopf N; Reinert T; Arendt T; Morawski M
    Acta Neuropathol Commun; 2021 Mar; 9(1):47. PubMed ID: 33752749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells.
    Garrido-Gil P; Rodriguez-Pallares J; Dominguez-Meijide A; Guerra MJ; Labandeira-Garcia JL
    Exp Neurol; 2013 Dec; 250():384-96. PubMed ID: 24184051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron dyshomeostasis in Parkinson's disease.
    Salazar J; Mena N; Núñez MT
    J Neural Transm Suppl; 2006; (71):205-13. PubMed ID: 17447431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron-binding characteristics of neuromelanin of the human substantia nigra.
    Double KL; Gerlach M; Schünemann V; Trautwein AX; Zecca L; Gallorini M; Youdim MB; Riederer P; Ben-Shachar D
    Biochem Pharmacol; 2003 Aug; 66(3):489-94. PubMed ID: 12907248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
    Jellinger KA
    Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione, iron and Parkinson's disease.
    Bharath S; Hsu M; Kaur D; Rajagopalan S; Andersen JK
    Biochem Pharmacol; 2002 Sep; 64(5-6):1037-48. PubMed ID: 12213603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
    Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C
    Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra.
    Galazka-Friedman J; Bauminger ER; Koziorowski D; Friedman A
    Biochim Biophys Acta; 2004 Mar; 1688(2):130-6. PubMed ID: 14990343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial ferritin suppresses MPTP-induced cell damage by regulating iron metabolism and attenuating oxidative stress.
    You LH; Li Z; Duan XL; Zhao BL; Chang YZ; Shi ZH
    Brain Res; 2016 Jul; 1642():33-42. PubMed ID: 27017962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.